Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019–)Track EVgo Inc (EVGO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThis press release includes forward-looking statements about Verastem Oncology's strategy, future plans and prospects, including statements related to cash runway, the potential clinical value of various of its clinical trials, the timing of commencing and completing trials, including topline data reports, and potential for additional ...The latest price target for Verastem ( NASDAQ: VSTM) was reported by HC Wainwright & Co. on Monday, May 13, 2024. The analyst firm set a price target for 17.50 expecting VSTM to rise to within 12 ...BOSTON--(BUSINESS WIRE)--Jan. 24, 2023-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the “Preferred Stock”) to affiliates of BVF Partners L.P. in a private ...Investors. At Verastem Oncology, Inc. (NASDAQ: VSTM), we’re working to develop a portfolio of novel small-molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth. We’re pushing beyond what’s known about cancer treatment and working to deliver novel treatment approaches that address ...Price to Book. 11.61. Revenue Per Employee. N/A. Enterprise Value/EBITDA. -2.77. Get all financial information for Verastem Inc (VSTM) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much more.Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival ...NasdaqCM - Nasdaq Real Time Price • USD. Verastem, Inc. (VSTM) Follow. 4.1200 -8.0600 (-66.17%) At close: 4:00 PM EDT. 4.1703 +0.05 (+1.22%) After hours: 5:08 PM EDT. Conversations. Community ...Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Verastem (VSTM – Research Report) today and set a price target of $24.00.The company’s shares closed yesterday at $1.02 ...By: Brian Stuglik, CEO, Verastem Oncology. Over the past year, those of us working in pharmaceutical oncology R&D have watched with awe as industry colleagues worked together to speed vaccinations for COVID-19 from the lab to patients’ arms in record time. Breakthroughs in cancer research, typically don’t happen that quickly.Summary. Verastem's stock plummeted after updates showed reduced efficacy in cancer treatment trials, causing a reassessment of strategy. Updated clinical …View the latest Verastem Inc. (VSTM) stock price, news, historical charts, analyst ratings and financial information from WSJ.We are pleased to announce this well-deserved promotion to Chief Executive Officer.". Dan Paterson joined Verastem Oncology in 2011 and has served as Chief Operating Officer since 2014 and President since 2019. He has more than 30 years of experience at healthcare and biotechnology companies. At Verastem Oncology, he spearheaded the ...Inside Verastem, Inc.'s 10-K Annual Report: Other - Other Highlight. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a product candidate or if we experience significant delays in enrollment in any clinical trials, we could be required to ...By: Brian Stuglik, CEO, Verastem Oncology. Over the past year, those of us working in pharmaceutical oncology R&D have watched with awe as industry colleagues worked together to speed vaccinations for COVID-19 from the lab to patients’ arms in record time. Breakthroughs in cancer research, typically don’t happen that quickly.BOSTON, January 18, 2024--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug ...Verastem Inc End-of-Day Stock Quote Alert . Verastem Inc SEC Alert. Verastem Inc Calendar Alert . Verastem Inc News Alert. Email. Leave this field blank. Investor Contact. Julissa Viana. Investor Relations [email protected]. Ryan Porter. Argot Partners +1 212-600-1902 [email protected] Per Share - Diluted of $2.29; Earnings Per Share - Diluted, as Adjusted, of $6.86Total Sales of $7.9B; Net Flows of ($4.8B); Assets Under... HARTFORD, Conn., July 29, 2022...Verastem GAAP EPS of -$1.26: May 9: VCEL: Critical Insights From Vericel Analyst Ratings: What You Need To Know: May 9: BLFS: BioLife Solutions GAAP EPS of -$0.22, revenue of $31.7M: May 9: BLFS: BioLife Solutions Reports First Quarter 2024 Financial Results: May 9: VSTM: Verastem Oncology Reports First Quarter 2024 Financial Results and ...BOSTON, November 08, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the ...Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer. BOSTON, April 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Verastem, Inc. Common Stock (VSTM) Pre-Market Stock Quotes - Nasdaq offers pre ...Track ImmunityBio Inc (IBRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics (“GenFleet”).Fintel reports that on July 11, 2023, Truist Securities maintained coverage of Verastem (NASDAQ:VSTM) with a Buy recommendation. Analyst Price Forecast Suggests 349.13% UpsideBarinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. About Barinthus Bio. Our Technology.Verastem Oncology has come a long way from the major failure of its lead candidate defactinib to its first FDA approval. And it's done it with a drug that itself had a troubled past. Once an ...We are pleased to announce this well-deserved promotion to Chief Executive Officer.". Dan Paterson joined Verastem Oncology in 2011 and has served as Chief Operating Officer since 2014 and President since 2019. He has more than 30 years of experience at healthcare and biotechnology companies. At Verastem Oncology, he spearheaded the ...Track VinFast Auto Ltd. (VFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.4.00%. BEAT. Home. Symbol. VSTM. Earnings. Checkout Verastem Inc (VSTM) earnings results, EPS expectations and actual EPS values for both quarterly and annual periods. Discover whether VSTM beat the street expectations or not?Track Versus Systems Inc (VS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 22,500 shares of its common stock and the grant of 15,000 restricted stock units to one new employee. The stock options have an exercise price equal to $0.87 per share, the closing ...Brian Stuglik, RPh. Mr Stuglik served as the Chief Executive Officer (CEO) of Verastem Oncology from 2019 through 2023. Mr Stuglik is a global leader in the oncology pharmaceutical sector, having successfully developed, acquired, and launched several important oncology products across multiple tumor types and therapeutic approaches in his more ...Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Verastem Oncology's investigational RAF/MEK clamp, avutometinib, in combination with Amgen's KRAS G12C inhibitor, LUMAKRAS TM (sotorasib), for the treatment of patients ...See the latest Verastem Inc stock price (VSTM:XNAS), related news, valuation, dividends and more to help you make your investing decisions.10.86. +3.43%. Discover historical prices for VSTM stock on Yahoo Finance. View daily, weekly or monthly format back to when Verastem, Inc. stock was issued.Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle ...Verastem Oncology | 13,729 followers on LinkedIn. Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and ...Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. About Barinthus Bio. Our Technology. Our Pipeline.Find the latest Verastem, Inc. (VSTM) stock quote, history, news and other vital information to help you with your stock trading and investing.Verastem, Inc. (NASDAQ:VSTM – Get Free Report) saw a significant decrease in short interest in March. As of March 31st, there was short interest totalling 634,500 shares, a decrease of 17.9% ...Track Netlist Inc (NLST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology has come a long way from the major failure of its lead candidate defactinib to its first FDA approval. And it's done it with a drug that itself had a troubled past. Once an ...Interactive stock price chart for Verastem, Inc. (VSTM) with real-time updates, full price history, technical analysis and more.Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways.Latest VPER News. No VPER news at the moment. Track Viper Networks, Inc. (VPER) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.Track Rail Vision Ltd (RVSN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsMay. 25, 2023, 09:05 PM. In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Hold rating on Verastem ( VSTM – Research Report ), with a price target of $2.00. The ...Track Tempest Therapeutics Inc (TPST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors6 equities research analysts have issued 1 year price objectives for Verastem's shares. Their VSTM share price targets range from $17.50 to $36.00. On average, they expect the company's share price to reach $28.79 in the next year. This suggests a possible upside of 598.7% from the stock's current price.Track Vistra Corp (VST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem stock resides in the small cap universe with a market cap of $263M and a share price of $10.43 which is closing in on its 52-week high share price of $15.12. Over the past year, the stock ...Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress. PDF Version. Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer.Price to Book. 11.61. Revenue Per Employee. N/A. Enterprise Value/EBITDA. -2.77. Get all financial information for Verastem Inc (VSTM) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much more.A few Evernote apps will no longer be updated or available for download in the new year. These include screenshot and annotating tool Skitch and Clearly, which makes web pages more...Track Novo Nordisk A/S (NVO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe Verastem stock price fell by -66.17% on the last day (Friday, 24th May 2024) from $12.18 to $4.12. During the last trading day the stock fluctuated 30.60% from a day low at $4.02 to a day high of $5.25. The price has been going up and down for this period, and there has been a -65.23% loss for the last 2 weeks.. We would like to show you a description here but the site For many patients with difficult-to-treat Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS pathway-driven tumors as part of its (Raf And Mek Program). RAMP 301 is a planned Phase 3 ... 1. ERK constantly suppresses upstream RAF signaling. P 1. ERK constantly suppresses upstream RAF signaling. Phospho-ERK inhibition by MEK-only inhibitors attenuates this suppressive signal to activate RAF kinase and reinvigorate tumor growth. MEK-only inhibition also induces phosphorylation and compensatory parallel pathway activation of FAK and potentially other parallel pathway signaling nodes ... TPG readers chimed in to tell us which brands of hotel soap...
Continue Reading